AngioDynamics Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone. Thank you for joining us for Canaccord Genuity's 2026 MedTech, Diagnostics, Digital Health & Services Forum. My name is John Young, and I am one of the analysts here at Canaccord. It is my pleasure to be joined today by Eric Honroth, who officially steps into the President and CEO role of AngioDynamics on November 2nd, and I believe this is his first public-facing commentary we have had since doing that. Eric brings more than 20 years of medical device and life sciences leadership experience to the company. We are also joined by CFO Stephen Trowbridge. Just to start, for investors who are new to the story, can you just give us an overview of AngioDynamics and where the company is today?
Absolutely. First of all, I am extremely excited about the future of AngioDynamics, and I think that the company has been on a milestone journey. Started in 1988 as mostly an interventional radiology company doing a number of different types of diagnostic catheters. Jim, Steve, and the team have led this transformational journey, and what we have come to at this point is a strong focus on cardiovascular and oncology, and you can see that permeate through all of our businesses. There are really core areas that those are the spots that we are going to continue to focus, put our time and attention, and make sure that we find the way to win.
With that, the business at this point is still broken up into what we have, our medical device area, which is some of our slower growth and some of our legacy product areas, and then our high growth, high margin, double digit when it comes to the MedTech area. Once again, laser focused on cardiovascular, endovascular, and also oncology.
Awesome. Then I think for investors meeting you for the first time, Eric, just what experiences from your career, from BSX to Abbott, do you draw on most in this role?
Yeah, absolutely. First of all, very excited to be a part of this. For those that know, I have a long history in medical device. I will just kind of walk everyone through that. Over the last four years, I was on the life science side, more in the cell and gene therapy, molecular therapy, and biopharma, running a global business for Getinge. That was a very important business for me to be in. But prior to that, all of my time and attention has been in medical device, both urology as well as cardiovascular. So companies like you mentioned, Boston Scientific, Abbott Vascular, Getinge, Becton Dickinson. This was a coming home for me. This was a really great opportunity for me to go into fields that I know a lot about. I have strong KOL relationships.
I know what it takes like to win. Traditionally, I have built some very strong and well-performance teams that I am looking forward to being a part of. When I got a chance to look at my history and the things that I have done, getting a chance to be part of AngioDynamics was a great fit, and why I am really excited about it.
To follow up on that too, you have obviously run some large businesses, but what are you most looking forward to about being a CEO of a public-facing company?
Yeah. First of all, I joined AngioDynamics and some of the other businesses because of the great products, right? Truly, AngioDynamics has got game-changing type technology. I love being customer-facing. I love getting out there with our physicians, our clinicians, and better understanding how we can impact the decisions they are making. To me, I love that and looking forward to it. But also, for the first time as a CEO, getting a chance to work closely with our investors. It is not something that I have done to that level.
I've done it before in a different chair, but this is an opportunity to work closely with them, understand what they like about the company, understand their suggestions and their thoughts, and help us to craft the long-term strategy that is going to provide that double-digit growth and the profitability that has been so incumbent in what we're doing. I'm looking forward to that for sure.
Nice. Yeah, I thought Eric was going to say what he was looking forward to most was reporting on arbitrary three-month timelines and having 40 million owners.
Yes. I think, too, just it sounds like you're making the most of it, but just any thoughts on just how you're approaching this transition period, and perhaps also, I know investors love hearing the 100-day plan.
Yeah. Any early outlines of what that 100-day plan could look like?
I would love to say that I've built a robust strategic plan in week one. I have not. I'm just going to be forthright. That will be forthcoming, and we will definitely be putting the time and attention. Let me just kind of detail. First of all, we are going to be very action-oriented because I do feel like there is significant opportunity and continued growth here. Secondarily, I want to be a really good listener, and I'll kind of go through what that listening plan looks like. First and foremost, last week, I spent a good bit of time with my executive leadership team understanding where we play, how we win, and what are the key areas that we're going to drive success. That was first, and I will continue doing that with key members of the AngioDynamics organization.
Secondarily, and I pivot to this, end of this week, customer-facing. I'm going to be with one of our super user programs in Nashville, and I love getting a chance to work closely with customers. I want to understand where our technology is meeting and exceeding their needs, and what are things that we need to continue to do to drive that type of value for them. Also, what does innovation look like? I'm a big fan of new product development, but also, what is innovation that they need to continue to accelerate with their practices? That's the second leg, if you will. Finally, as evidenced by this week, a lot of time with investors. I think that when we look at the AngioDynamics story, it sometimes is a little bit of a complicated one.
I think that some of that nuance is probably lost a little bit in how we can continue to showcase all the important things that we're doing and how we can continue to drive growth. I do want to focus and lean in with the investor community just to understand and obviously figure out, especially on that strategic plan, which I will launch, especially as we go into next year, a better idea as to where we want to focus our time and attention.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
